Does Doxazosin Attenuate Stress-induced Smoking and Improve Clinical Outcomes?

• Status: Completed
• Trial end date: 2016-11-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to examine whether doxazosin will attenuate the ability of stress to precipitate smoking lapse behavior in treatment seeking daily smokers. Participants will participate in a smoking cessation attempt after the laboratory sessions.

• Phase: Phase 2
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Yale University
• Collaborator: National Institute on Drug Abuse (NIDA)
• Treatments: Doxazosin

Criteria

Inclusion Criteria:

• Ages 18-60

• Able to read and write English

• Smoker

• Motivated to Quit Smoking

Exclusion Criteria:

• Any significant current medical conditions that would contraindicate smoking

• Current Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) abuse or dependence of other substances, other than nicotine dependence or alcohol abuse

• Positive test results at intake appointment on urine drug screens for illicit drugs

• Past 30 day use of psychoactive drugs including anxiolytics and antidepressants

• Women who are pregnant or nursing

• Suicidal, homicidal or evidence of current severe mental illness such as schizophrenia, bipolar disorder or major depression, or anxiety disorders

• Participants who have donated blood within the past 6 weeks

• Individuals who are currently taking other medications prescribed for smoking cessation

• Specific exclusions for administration of doxazosin or any alpha blocker